These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18221085)

  • 1. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: from basic science to clinical practice.
    Parissis JT; Rafouli-Stergiou P; Paraskevaidis I; Mebazaa A
    Heart Fail Rev; 2009 Dec; 14(4):265-75. PubMed ID: 19101796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levosimendan in cardiology and intensive care medicine].
    Delle Karth G; Heinz G
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):6-14. PubMed ID: 15030117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
    Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan for the treatment of acute heart failure syndromes.
    Parissis JT; Filippatos G; Farmakis D; Adamopoulos S; Paraskevaidis I; Kremastinos D
    Expert Opin Pharmacother; 2005 Dec; 6(15):2741-51. PubMed ID: 16316312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.